| Comparative risk of serious infections with biologic agents and oral small molecules in inflammatory bowel diseases: a systematic review and meta-analysis V Solitano, A Facciorusso, T Jess, C Ma, C Hassan, A Repici, V Jairath, ... Clinical Gastroenterology and Hepatology 21 (4), 907-921. e2, 2023 | 42 | 2023 |
| Early intervention in ulcerative colitis: ready for prime time? V Solitano, F D’Amico, E Zacharopoulou, L Peyrin-Biroulet, S Danese Journal of Clinical Medicine 9 (8), 2646, 2020 | 41 | 2020 |
| Proactive therapeutic drug monitoring versus conventional management for inflammatory bowel diseases: a systematic review and meta-analysis NH Nguyen, V Solitano, SK Vuyyuru, JK MacDonald, SW Syversen, ... Gastroenterology 163 (4), 937-949. e2, 2022 | 40 | 2022 |
| The future of drug development for inflammatory bowel disease: the need to ACT (advanced combination treatment) S Danese, V Solitano, V Jairath, L Peyrin-Biroulet Gut 71 (12), 2380-2387, 2022 | 39 | 2022 |
| Sphingosine 1-phosphate modulation in inflammatory bowel diseases: keeping lymphocytes out of the intestine A Dal Buono, R Gabbiadini, L Alfarone, V Solitano, A Repici, S Vetrano, ... Biomedicines 10 (7), 1735, 2022 | 27 | 2022 |
| Ulcerative colitis: Impact of early disease clearance on long‐term outcomes‐A multicenter cohort study F D’Amico, G Fiorino, V Solitano, E Massarini, L Guillo, M Allocca, ... United European gastroenterology journal 10 (7), 775-782, 2022 | 26 | 2022 |
| Outcome of Sars-COV-2-related thyrotoxicosis in survivors of Covid-19: a prospective study A Pizzocaro, P Colombo, W Vena, S Ariano, P Magnoni, F Reggiani, ... Endocrine 73 (2), 255-260, 2021 | 22 | 2021 |
| Key strategies to optimize outcomes in mild-to-moderate ulcerative colitis V Solitano, F D’Amico, G Fiorino, K Paridaens, L Peyrin-Biroulet, ... Journal of Clinical Medicine 9 (9), 2905, 2020 | 19 | 2020 |
| Rediscovering histology: what is new in endoscopy for inflammatory bowel disease? V Solitano, F D’Amico, M Allocca, G Fiorino, A Zilli, L Loy, D Gilardi, ... Therapeutic Advances in Gastroenterology 14, 17562848211005692, 2021 | 18 | 2021 |
| Nocebo effect and biosimilars in inflammatory bowel diseases: what’s new and what’s next? F D’Amico, V Solitano, L Peyrin-Biroulet, S Danese Expert Opinion on Biological Therapy 21 (1), 47-55, 2021 | 18 | 2021 |
| Fibro-stenosing Crohn’s disease: what is new and what is next? V Solitano, A Dal Buono, R Gabbiadini, M Wozny, A Repici, A Spinelli, ... Journal of Clinical Medicine 12 (9), 3052, 2023 | 17 | 2023 |
| HLA-DQA1∗ 05 genotype and immunogenicity to tumor necrosis factor-α antagonists: a systematic review and meta-analysis V Solitano, A Facciorusso, DPB McGovern, T Nguyen, RJ Colman, L Zou, ... Clinical Gastroenterology and Hepatology 21 (12), 3019-3029. e5, 2023 | 16 | 2023 |
| Biobetters in patients with immune-mediated inflammatory disorders: an international Delphi consensus F d'Amico, V Solitano, D Aletaha, A Hart, F Magro, C Selmi, SC Ng, ... Autoimmunity Reviews 20 (7), 102849, 2021 | 16 | 2021 |
| Advanced combination treatment with biologic agents and novel small molecule drugs for inflammatory bowel disease V Solitano, C Ma, J Hanžel, R Panaccione, BG Feagan, V Jairath Gastroenterology & Hepatology 19 (5), 251, 2023 | 15 | 2023 |
| Thrombosis in IBD in the Era of JAK Inhibition V Solitano, G Fiorino, F d'Amico, L Peyrin-Biroulet, S Danese Current Drug Targets 22 (1), 126-136, 2021 | 15 | 2021 |
| Patient’s profiling for therapeutic management of inflammatory bowel disease: a tailored approach F D’Amico, G Fiorino, F Furfaro, M Allocca, G Roda, L Loy, A Zilli, ... Expert Review of Gastroenterology & Hepatology 14 (9), 765-773, 2020 | 15 | 2020 |
| Serum ANCA as disease biomarkers: clinical implications beyond vasculitis M Folci, G Ramponi, V Solitano, E Brunetta Clinical Reviews in Allergy & Immunology 63 (2), 107-123, 2022 | 14 | 2022 |
| Efficacy of pharmacological agents for ulcerative proctitis: a systematic literature review B Caron, WJ Sandborn, R Panaccione, S Schreiber, A Hart, V Solitano, ... Journal of Crohn's and Colitis 16 (6), 922-930, 2022 | 14 | 2022 |
| Risk minimization of JAK inhibitors in ulcerative colitis following regulatory guidance S Danese, V Solitano, V Jairath, L Peyrin-Biroulet Nature Reviews Gastroenterology & Hepatology 20 (3), 129-130, 2023 | 13 | 2023 |
| Biosimilar switching in inflammatory bowel disease: from evidence to clinical practice V Solitano, F D’Amico, G Fiorino, L Peyrin-Biroulet, S Danese Expert Review of Clinical Immunology 16 (10), 1019-1028, 2020 | 13 | 2020 |
